COVID-19 (Coronavirus) Update

A Phase 1/2, Dose Escalation Safety And Tolerability Study Of AO-176 As Monotherapy And In Combination With Bortezomib And Dexamethasone In Adults With Relapsed Or Refractory Multiple Myeloma

Protocol No
ARCH-AO-176-102
Principal Investigator
Parameswaran Hari
Phase
I/II
Summary
In this study the focus of Phase 1 is safety, answering the question of which dose is tolerable. In Phase 2 the focus is on safety and whether the study drug, in combination with other drugs, help your cancer not continue or progress, answering the question of whether the study drug is effective.
Description
You are being asked to participate in this study because you have multiple myeloma and your disease has returned after receiving treatment (recurrent disease) or it is no longer responding to your most recent treatment (refractory disease). Arch Oncology, the sponsor of the clinical trial, is studying AO-176 by itself or in combination with either dexamethasone or with both dexamethasone and bortezomib, as a potential treatment for people with recurrent or refractory multiple myeloma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: